Kidney Week

Abstract: FR-PO0586

Efficacy After One Year of Ultrasound-Based Renal Denervation in Patients with ADPKD

Session Information

• CKM: Clinical - Meta-Analyses, Predictive Modeling, Care Delivery, and Safety
  October 23, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Cardiovascular-Kidney-Metabolic Health

• 602 Cardiovascular-Kidney-Metabolic Health: Clinical

Authors

• Schmieder, Roland E., Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Roland E. Schmieder, MD, FASN

• Schmid, Axel, Universitatsklinikum Erlangen Radiologisches Institut, Erlangen, BY, Germany

Axel Schmid, MD

• Bosch, Agnes, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Agnes Bosch, MD

• Kliem, Thorsten, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Thorsten Kliem, MD, DrMed

• Schiffer, Mario, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Mario Schiffer, MD, MBA

• Uder, Michael, Universitatsklinikum Erlangen Radiologisches Institut, Erlangen, BY, Germany

Michael Uder, MD

• Kannenkeril, Dennis, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Dennis Kannenkeril, MD

Background

Strict blood pressure (BP) control is recommended in patient with autosomal dominant polycystic kidney disease (ADPKD). Renal denervation (RDN) is now considered a treatment option for uncontrolled hypertension. Here, we report the efficacy of ultrasound-based RDN (uRDN) in patients with ADPKD during one year of follow-up.

Methods

In this trial (Clingov: NCT05460169), patients with ADPKD (eGFR ≥ 40 mL/min/1.73 m²) and uncontrolled hypertension (office BP ≥ 130/80 mmHg and 24-hour ambulatory BP ≥ 125/75 mmHg), despite taking one to four antihypertensive medications, were enrolled. Initially, patients were randomized to the immediately treated group or the delayed-treatment control group receiving uRDN after 13 weeks of waiting. Ultrasound-based RDN was performed using the PARADISE System (Recor Medical, Inc., USA). BP changes were analyzed using all three methods: office, 24-hour ambulatory, and home BP.

Results

The mean age of our patients with ADPKD (27 males and 17 females) was 42 years, and their mean eGFR was 74 mL/min/1.73 m². Office BP (122 ± 9 vs. 130 ± 12 mmHg, p = 0.019) and home systolic BP (129 ± 10 vs. 135 ± 8 mmHg, p = 0.036) were lower in the immediately treated group than in the control group 13 weeks after uRDN. Considering all patients together, significant reductions (all p < 0.01) were observed in office, home, and 24-hour ABP (systolic and diastolic) three, six and twelve months after uRDN compared to values prior to uRDN (12 months results see table). Patients with an eGFR between ≥ 40 and < 60 ml/min/1.73m² had a similar BP reduction after one year than those with an eGFR > 60 ml/min/1.73m² (all p> 0.20). No safety signals related to uRDN were identified during the one-year follow-up period.

Conclusion

Clinically meaningful reductions in systolic and diastolic BP were observed during one year after uRDN in patients with autosomal dominant polycystic kidney disease and uncontrolled hypertension. Heart rate was found to be decreased after uRDN as well. There were no safety concerns.

Acknowledgment

COI: funding by Recor Medical